HD-CAR-1

HD-CAR-1 is an **investigator-initiated, third-generation chimeric antigen receptor (CAR) T cell therapy** designed to target CD19, a surface antigen widely expressed on B-cell malignancies. The therapy utilizes autologous T lymphocytes genetically modified via a retroviral vector (RV-SFG.CD19.CD28.4-1BBzeta) to express a CAR containing two costimulatory domains: CD28 and 4-1BB (CD137), in addition to the CD3ζ signaling domain. This design aims to enhance anti-tumor efficacy and CAR T-cell persistence compared to previous generations. HD-CAR-1 is manufactured in-house at University Hospital Heidelberg. It is administered following lymphodepleting chemotherapy with fludarabine and cyclophosphamide. The therapy has demonstrated **encouraging efficacy and a favorable safety profile** in patients with relapsed/refractory (r/r) B-cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and acute lymphoblastic leukemia (ALL). Notably, HD-CAR-1 therapy was associated with low rates of severe cytokine release syndrome (CRS) and neurotoxicity, and was tolerated by patients with prior allogeneic stem cell transplantation[1][2][4][6][8][9].

Other names

CD19.CAR T CellsCD-19.CAR T CellsCD 19.CAR T Cellsthird-generation CD19 CAR T cellsCD19.CAR T Cells-University Hospital HeidelbergCD-19.CAR T Cells-University Hospital HeidelbergCD 19.CAR T Cells-University Hospital Heidelberg